Variable behavior of iPSCs derived from CML patients for response to TKI and hematopoietic differentiation.

Variable behavior of iPSCs derived from CML patients for response to TKI and hematopoietic differentiation.

Chronic myeloid leukemia disease (CML) found effective therapy by treating patients with tyrosine kinase inhibitors (TKI), which suppress the BCR-ABL1 oncogene activity. However, the majority of patients achieving remission with TKI still have molecular evidences of disease persistence. Various mech...

Full description

Bibliographic Details
Main Authors: Aurélie Bedel, Jean-Max Pasquet, Eric Lippert, Miguel Taillepierre, Valérie Lagarde, Sandrine Dabernat, Pierre Dubus, Lucie Charaf, François Beliveau, Hubert de Verneuil, Emmanuel Richard, François-Xavier Mahon, François Moreau-Gaudry
Format: Article
Language:English
Published: Public Library of Science (PLoS) 2013-01-01
Series:PLoS ONE
Online Access:http://europepmc.org/articles/PMC3751925?pdf=render

Internet

http://europepmc.org/articles/PMC3751925?pdf=render

Similar Items